Big Pharma Bottom Feeders’ Gold Rush Greed
Big Pharma Bottom Feeders’ Gold Rush Greed By Robert Carter/January 31, 2026 Big Pharma remains one of the most profitable industries on the planet with an annual net income profit of almost 14 percent. That’s almost twice the profit margin in other major industries. Pharmaceutical companies have more than enough money to spread around, even for their funding of 75 percent of the FDA’s pharmaceutical division. You ask, isn’t there an ethical conflict of interest there for the FDA? Probably…but when there’s that much money spilling over the top of those high profit margins, it’s easy for a kind of gold rush mentality to take over from any ethical considerations. A recent court case has brought to light a small pocket of some bottom feeders for Big Pharma wealth which have appeared in the Miami area. Dubbed “contract research organizations,” these carpetbagger clinical trial conductors are hired by pharmaceutical companies and private investors to do the research for prospective drugs so they can be approved by the FDA and introduced to the market. In July, 2025, drug developer T3D Therapeutics filed a legal complaint against the contract research organization they had hired to do research on a prospective drug that stimulates the brain’s ability to process sugar and thereby reduce cognitive decline in Alzheimer’s patients. Of course, that T3D idea was based on the chemical imbalance theory that has been so thoroughly debunked since Big Pharma began marketing it back in the 1980s. In any case, when T3D began examining the results from the $35 million trial, underwritten by private and government funding, they discovered a “medically impossible” collection of unusable data that was virtually all fraudulent. Clinilabs had been hired to manage the five Miami area clinics doing the research, but these for-profit firms had been using unqualified trial participants as well as using questionable clinical trial protocol. Some of their reported positive results were simply outright lies. Trial sites like these in Miami have been involved in more than 11,000 trials. South Florida has become a lucrative area for the $85 billion contract research business because of the high average age of its residents, which appeals to drug manufacturers. Older trial participants are apparently more easily recruited with the high fees paid, the lavish food provided them, and the “cognitive difficulties” they might claim which are so easy to fake. In fact, a small community of “professional patients” has sprung up in Miami and elsewhere to reap the financial rewards available. Many of them have been found to just covertly dump the experimental pills they are supposed to take rather than risk any potentially dangerous side effects from them. Gold rush ethics beget gold rush ethics all the way down the line. So, how trustworthy are the results of any of the thousands and thousands of these new drug trials that are being done? The only thing trustworthy is the accuracy of the ledger entries for the millions being invested and then being pocketed by these gold rush, bottom feeder, contracted research organizations.

